登录 | 注册    微信公众号  
搜索
 > 【B7-1】

B7-1信息

英文名称:Cluster of differentiation 80
中文名称:分化群80
靶点别称:Activation B7-1 antigen,LAB7,T-lymphocyte activation antigen CD80,CD80 Molecule,CD80 Antigen (CD28 Antigen Ligand 1, B7-1 Antigen),B-Lymphocyte Activation Antigen B7,CTLA-4 Counter-Receptor B7.1,CD28LG1,BB1,Costimulatory Molecule Variant IgV-CD80,Costimulatory Factor CD80,CD80 Antigen,B7-1,B7.1,B7-1 Antigen,B7,CD80,CD28LG
上市药物数量:2
临床药物数量:3
最高研发阶段:批准上市

B7-1产品列表

 
评论(9)
B71-H5228|Human B7-1 / CD80 Protein, His Tag (MALS verified)
  1. 138XXXXXXX8
  2. 3人赞
  3. 之前的实验结果总是不太理想,想着换个产品试试,没想到这个品牌做出的结果很稳定,解决了一直困扰我们的问题,非常满意,希望品牌越来越好。
  4. 2022-04-22
B71-H5228|Human B7-1 / CD80 Protein, His Tag (MALS verified)
  1. 152XXXXXXX7
  2. 1人赞
  3. 我们使用该试剂应用于免疫组化实验,经过数轮实验,结果非常优秀:反应迅速,显色清晰,且消耗量不算大,性价比在同类型试剂中显得较高。
  4. 2022-04-22
B71-H5228|Human B7-1 / CD80 Protein, His Tag (MALS verified)
  1. 188XXXXXXX0
  2. 2人赞
  3. 我们用这个试剂进行抗原结合活性得实验,实验的结果完全符合我们的预期,可以进行下一步的验证实验,另外这个抗原地说明书很全面,售后也好,任何问题都很耐心的解答。
  4. 2022-04-22
 

B7-1 分子别名

CD80,B7,B7-1,B7.1,BB1,CD28LG,CD28LG1,LAB7

B7-1 分子背景

B7-1 and B7-2, together with their receptors CD28 and CTLA­4, constitute one of the dominant co-stimulatory pathways that regulate T­ and B­cell responses. Although both CTLA­4 and CD28 can bind to the same ligands, CTLA­4 binds to B7­1 and B7­2 with a 20 ­ 100 fold higher affinity than CD28 and is involved in the down­regulation of the immune response.B-lymphocyte activation antigen B7-1 (referred to as B7) also known as cluster of Differentiation 80 (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activated B cells, activated T cells, macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. CD80 plays a role in induction of innate immune responses by activating NF-κB-signaling pathway in macrophages. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.

B7-1 前沿进展

B7-1上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Belatacept LEA29Y; LEA-029; BMS-224818; L104EA29YIg 批准上市 百时美施贵宝 Nulojix EU 肾脏移植排斥 Bristol-Myers Squibb Pharma Eeig 2011-06-15 肾脏移植排斥, 器官移植排斥 详情
Abatacept 阿巴西普 ONO-4164; BMS-188667; BMS-188667SC; ONO-4164SC 批准上市 百时美施贵宝 Orencia United States 移植物抗宿主病 Bristol Myers Squibb Srlcompany 2005-12-23 微小病变性肾病, 克罗恩病, 肌病, 肾病综合征, 银屑病关节炎, 溃疡性结肠炎, 银屑病, 系统性红斑狼疮, 局灶性节段性肾小球硬化症, 多发性硬化, 多发性肌炎, 狼疮肾炎, 幼年型类风湿性关节炎, 新型冠状病毒肺炎, 移植物抗宿主病, Sjtoegren综合征, 类风湿关节炎, 肌炎, 皮肌炎 详情

B7-1临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
rVV-740CTA vaccine (University Hospital Basel) rVV-740CTA 临床一期 University Hospital Basel 乳腺癌 详情
Belatacept biosimilar (Alphamab) KN-019 临床二期 苏州康宁杰瑞生物科技有限公司 肾脏移植排斥, 类风湿关节炎, 自身免疫疾病 详情
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) Z-CTLs 临床一期 湖南昭泰涌仁医疗创新有限公司 非小细胞肺癌 详情
IAB22M2C IAB-22-M2C 临床二期 Imaginab Inc 实体瘤, Merkel细胞癌, 肾细胞癌, 黑色素瘤, 非小细胞肺癌 详情

消息提示

请输入您的联系方式,再点击提交!

确定